Catalyst Pharmaceuticals
Yahoo Finance • 2 months ago
Despite lower earnings than three years ago, Catalyst Pharmaceuticals (NASDAQ:CPRX) investors are up 293% since then
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But in contrast you can make much more than 100% if the company does well. For example, the Catalyst Pharmaceuti... Full story
Yahoo Finance • 6 months ago
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
Despite some turbulence, growth stocks have been on a bull run since the 2008 financial crisis. Groundbreaking innovations in technology and healthcare have been the primary drivers behind this trend. Which growth stocks stand out as top... Full story
Yahoo Finance • 7 months ago
Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024
In this article, we will take a detailed look at Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024. For a quick overview of such stocks, read our article Jim Cramer’s 5 Favorite Healthcare Stock Picks in 2024. Jim Cramer kicked off... Full story
Yahoo Finance • 12 months ago
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for p... Full story
Yahoo Finance • 12 months ago
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $(0.29) Diluted, Impacted by an $81.5 Million One Time Non-Recurring IPR&D Expense Related to the Acquisition of A... Full story
Yahoo Finance • 12 months ago
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story
Yahoo Finance • last year
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story
Yahoo Finance • last year
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy and Other... Full story
Yahoo Finance • last year
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
CORAL GABLES, Fla., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for p... Full story
Yahoo Finance • last year
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story
Yahoo Finance • last year
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and C... Full story
Yahoo Finance • last year
2 Robinhood Stocks With Market-Beating Potential
The Robinhood trading platform helped introduce fee-free trading when it debuted in 2015, and the platform remains popular because of its easy-to-use app that even allows investors to buy fractional shares. Two stocks on the list that stan... Full story
Yahoo Finance • last year
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL GABLES, Fla., Oct. 13, 2023 (GLOBE NEWS... Full story
Yahoo Finance • last year
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for... Full story
Yahoo Finance • last year
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers of CHF 3.9 million (H1-2022: CHF 6.... Full story
Yahoo Finance • last year
Santhera gibt die Finanzergebnisse für das Halbjahr 2023 bekannt und informiert über den aktuellen Stand des Unternehmens
Ad-hoc-Mitteilung gemäss Art. 53 KR Santhera wird heute um 14:30 MESZ / 13:30 BST / 08:30 EDT eine Telefonkonferenz durchführen. Details dazu am Ende dieser Mitteilung. Umsätze aus Verträgen mit Kunden in Höhe von CHF3,9 Millionen (H1-20... Full story
Yahoo Finance • last year
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing nove... Full story
Yahoo Finance • last year
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel... Full story
Yahoo Finance • last year
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation for Vamorolone to Tre... Full story
Yahoo Finance • last year
Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:3 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera will receive USD 90million upfrontat closing (USD75 million in ca... Full story
